QPEX BIOPHARMA is developing a pipeline of agents addressing critical needs for the treatment of infectious diseases in the inpatient and outpatient settings.

Qpex management has a record of deep expertise in the discovery, development, and regulatory approval of anti-infective medicines, including an extensive record of working with public/private partnerships focused on new antibiotics to combat antimicrobial resistance.

The Unmet Need

The COVID-19 pandemic teaches important lessons about untreatable infectious diseases

 

The COVID-19 pandemic reminds us how an untreatable infectious disease can spread quickly, overwhelm health care systems, and result in patient morbidity and mortality that was unthinkable to many.

 

While there is hope in innovation of new treatment and vaccines, we now understand what it is like to have untreatable infections. Antimicrobial drug resistance (AMR) has been a slowly moving pandemic with similar but important differences from COVID-19. The difference is that society has enjoyed the benefits of active antibiotics to treat bacterial infections but is now losing them.

Our Approach

DEFINE

drug resistance mechanisms

 

IMPROVE

existing proven classes of drugs

FIND

new chemical classes of drugs that overcome drug resistance

Reversing antibiotic resistance

Making antibiotics work better

We have important partnerships and we communicate the optimal use of our products

COLLABORATE

DISCOVERY

ENZYME INHIBITION

COMBINE